Share Price | CG Oncology, Inc. Stock Analysis & Recommendation

Q: Is CG Oncology, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for CG Oncology, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong indication from the daily moving averages and the weekly MACD, KST, and Bollinger Bands all showing bullish signals. However, the weekly RSI is bearish, which suggests some caution. The Dow Theory and OBV indicate a mildly bullish trend on both weekly and monthly time frames. In terms of performance, CG Oncology has significantly outperformed the S&P 500 over the past week (17.07% vs. 1.05%) and month (48.56% vs. 2.33%), while trailing over the past year (4.75% vs. 17.14%).

Q: Is CG Oncology, Inc. overvalued or undervalued?

As of 13 May 2025, the valuation grade for CG Oncology, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently classified as overvalued, given its high Price to Book Value of 2.91 and extremely negative ratios such as EV to EBIT and EV to EBITDA at -11.89. Additionally, the Return on Capital Employed (ROCE) is alarmingly low at -691.63%, which raises concerns about the company's operational efficiency.In comparison with peers, CG Oncology, Inc. shows a stark contrast, with its EV to EBITDA ratio of -11.4449 compared to the industry average. Notably, its performance has lagged behind the S&P 500, with a year-to-date return of -10.53% versus the index's 2.44%. Given these metrics, it is clear that CG Oncology, Inc. is not only overvalued but also struggling significantly in its operational performance.

Q: How big is CG Oncology, Inc.?

Market Cap: As of Jun 18, CG Oncology, Inc. has a market capitalization of 2,000.15 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, CG Oncology, Inc. reported net sales of 0.66 million and a net profit of -105.56 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 733.38 million and total assets of 754.80 million.

Q: What does CG Oncology, Inc. do?

Overview: CG Oncology, Inc. operates in the miscellaneous industry and is classified as a small-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) Market cap: USD 2,000.15 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.98 Return on Equity: -12.49% Price to Book: 2.84Contact Details: Details: No Company Details Available Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

503.59 k

Shareholding (Mar 2026)

FII

20.93%

Held by 112 FIIs

DII

56.94%

Held by 47 DIIs

Promoter

22.12%

Is CG Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, CG Oncology, Inc. has shifted to a bullish trend, supported by strong daily moving averages and weekly indicators, though caution is advised due to a bearish weekly RSI, while it has outperformed the S&P 500 significantly over the past week and month but lagged over the past year.

View full answer

Is CG Oncology, Inc. overvalued or undervalued?

25-Jun-2025

As of May 13, 2025, CG Oncology, Inc. is classified as overvalued with a valuation grade of "does not qualify" due to extremely negative financial ratios and poor operational performance, including a Return on Capital Employed of -691.63% and a year-to-date return of -10.53%.

View full answer

How big is CG Oncology, Inc.?

22-Jun-2025

As of Jun 18, CG Oncology, Inc. has a market capitalization of $2,000.15 million, with net sales of $0.66 million and a net profit of -$105.56 million over the latest four quarters. The company reported shareholder's funds of $733.38 million and total assets of $754.80 million as of Dec 24.

View full answer

What does CG Oncology, Inc. do?

22-Jun-2025

CG Oncology, Inc. is a small-cap company in the miscellaneous industry, reporting net sales of $0 million and a net loss of $34 million as of March 2025. It has a market cap of approximately $2 billion and does not pay dividends.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at USD -160.01 MM
RAW MATERIAL COST(Y) Grown by 437.35% (YoY)
OPERATING PROFIT(Q) Lowest at USD -65.55 MM

Risky -

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 5,456 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.98

Return on Equity

-21.39%

Price to Book

7.25

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Mar 2026)

Net Profit:

-60 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.09%

6 Months

76.87%

1 Year

173.27%

2 Years

125.06%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

CG Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

120.00%

EBIT Growth (5y)

-220.02%

EBIT to Interest (avg)

-60.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.25

EV to EBIT

-24.73

EV to EBITDA

-24.92

EV to Capital Employed

328.50

EV to Sales

1167.81

PEG Ratio

Dividend Yield

ROCE (Latest)

-1328.32%

ROE (Latest)

-21.39%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 57 Schemes (35.79%)

Foreign Institutions

Held by 112 Foreign Institutions (20.93%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 1,000.00% vs -80.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -74.49% vs -104.14% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.10",
          "val2": "0.10",
          "chgp": "1,000.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.50",
          "val2": "-42.20",
          "chgp": "-55.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-60.20",
          "val2": "-34.50",
          "chgp": "-74.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-61,301.00%",
          "val2": "-811,615.40%",
          "chgp": "75,031.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 263.64% vs 450.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -82.95% vs -81.07% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.00",
          "val2": "1.10",
          "chgp": "263.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-189.30",
          "val2": "-114.60",
          "chgp": "-65.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-161.00",
          "val2": "-88.00",
          "chgp": "-82.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-47,221.30%",
          "val2": "-100,672.50%",
          "chgp": "5,345.12%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

1.10

0.10

1,000.00%

Operating Profit (PBDIT) excl Other Income

-65.50

-42.20

-55.21%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-60.20

-34.50

-74.49%

Operating Profit Margin (Excl OI)

-61,301.00%

-811,615.40%

75,031.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 1,000.00% vs -80.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -74.49% vs -104.14% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

4.00

1.10

263.64%

Operating Profit (PBDIT) excl Other Income

-189.30

-114.60

-65.18%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-161.00

-88.00

-82.95%

Operating Profit Margin (Excl OI)

-47,221.30%

-100,672.50%

5,345.12%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 263.64% vs 450.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -82.95% vs -81.07% in Dec 2024

All Annual Results

Company CV

About CG Oncology, Inc.

CG Oncology, Inc.

Miscellaneous

No Details Available.

Company Coordinates

No Company Details Available